#### **ENDURING MATERIAL LEARNER NOTIFICATION**

Med Learning Group
Reducing the Burden and Cost of Chronic Spontaneous Urticaria
May 31, 2022 – May 31, 2023
Online

## **Acknowledgement of Financial Commercial Support**

Sanofi Genzyme and Regeneron Pharmaceuticals

## **Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

#### **Satisfactory Completion**

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

#### **Accreditation Statement**



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

# Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

Amedco LLC designates this activity for a maximum of 1.50 knowledge-based CPE contact hours.

UAN(s): JA4008163-9999-22-102-H04-P / JA4008163-9999-22-102-H04-T

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

## Objectives - After Attending This Program You Should Be Able To

- Quantify the economic, physical and psychosocial burden of CSU.
- 2. Assess treatment plans for adherence to guideline recommended therapy and consideration of patient-specific factors.
- 3. Evaluate clinical trial data on the efficacy and safety of available and emerging biologics for CSU.

# **Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Felecia	Beachum	NA
		Amgen, AstraZeneca, Calldex, Genentech, Novartis, Sanofi/Regeneron: Consultant,
		Amgen, AstraZeneca, Calldex, Genentech, Novartis, Sanofi/Regeneron: Contract
		Research, AstraZeneca, Genentech, Novartis, Sanofi/Regeneron: Speaker Bureau,
Jonathan	Bernstein	AstraZeneca, Genentech, Novartis, Sanofi/Regeneron: Other
Douglas	Cox	NA
Daniel	DaSilva	NA
Angela	Davis	NA
Naomi	De Brito	NA
Matthew	Frese	NA
Christina	Gallo	NA

Jo	Shultz	NA
Geoffrey	Wall	Janssen, Tetraphase: Speaker Bureau
Lauren	Welch	NA

# **How to Get Your Certificate**

- 1. Go to http://mlg.cmecertificateonline.com/
- 2. Click on the "Enduring Reducing the Burden and Cost of Chronic Spontaneous Urticaria" link.
- 3. Evaluate the meeting and click the hyperlink provided on the last page to claim your credit certificate.
- 4. Save/Download/Print all pages of your certificate for your records.

Questions? Email <a href="mailto:Certificate@AmedcoEmail.com">Certificate@AmedcoEmail.com</a>